UCB reported EUR2.96B in Operating Expenses for its fiscal semester ending in December of 2025.





Operating Expenses Change Date
Alcon AG USD 2.36B 423M Sep/2026
Almirall EUR 531.16M 13.76M Jun/2026
Amarin USD 51.48M 113K Dec/2025
argenx SE USD 1.24B 213M Sep/2026
AstraZeneca USD 11.55B 674M Sep/2026
Bayer EUR 9.92B 121M Sep/2026
Genmab DKK 748M 77M Jun/2026
GlaxoSmithKline GBP 6.03B 227M Sep/2026
GRIFOLS EUR 1.65B 101M Sep/2026
Hikma Pharmaceutical USD 1.34B 702M Dec/2025
Lakefront Biotherapeutics EUR 48.75M 6.87M Sep/2026
Lonza CHF 2.9B 184M Jun/2025
Merck EUR 4.97B 630M Sep/2026
Novartis USD 9.88B 325M Sep/2026
Orion EUR 332.3M 12.7M Sep/2026
Recordati EUR 485.55M 8.04M Sep/2026
Roche Holding CHF 18.9B 2.12B Jun/2026
Sanofi EUR 10.51B 598M Sep/2026
UCB EUR 2.96B 196M Dec/2025
Unibail Rodamco EUR 646.6M 25.4M Dec/2025